SCHEMBL6770137

SCHEMBL6770137

Cn1c(N2CCN(CCCCC3(C(=O)NCc4ccc(F)cc4)c4ccccc4-c4ccccc43)CC2)nc2cccnc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 1/20 0.41
HTR1A P08908 7/20 0.41
HTR7 P34969 5/20 0.41
DRD2 P14416 4/20 0.41
HTR6 P50406 2/20 0.41
ALDH1A1 P00352 2/20 0.40
ENPP2 Q13822 2/20 0.40
TP53 P04637 2/20 0.39
RXFP1 Q9HBX9 1/20 0.39
DRD1 P21728 3/20 0.39
DRD3 P35462 3/20 0.39
DRD5 P21918 2/20 0.39
HTR2A P28223 2/20 0.39
MTTP P55157 2/20 0.39
CHRM2 P08172 1/20 0.39
ADRA2A P08913 1/20 0.39
ADORA3 P0DMS8 1/20 0.39
CHRM1 P11229 1/20 0.39
TBXA2R P21731 1/20 0.39
PTGS1 P23219 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6766930 0.91 ALDH1A1 (0.51) HTR1AHTR7ALDH1A1TP53RXFP1
SCHEMBL6770188 0.88 MTTP (0.51) DRD1DRD3MTTPCHRM2ADRA2A
SCHEMBL6771800 0.88 ALDH1A1 (0.43) HTR1AHTR7DRD2HTR6ALDH1A1
SCHEMBL6770753 0.85 KMT2A (0.51) ALDH1A1CHRM1HRH1LMNAMAPT
SCHEMBL6771866 0.85 ALDH1A1 (0.58) HTR1AHTR7DRD2ALDH1A1TP53
SCHEMBL6771603 0.83 HTR1A (0.45) HTR1AHTR7DRD2ALDH1A1DRD1
SCHEMBL6769580 0.82 HTR1A (0.44) HTR1AHTR7DRD2DRD1DRD3
SCHEMBL6766415 0.82 HTR1A (0.51) HTR1AHTR7DRD2DRD3HTR2A
SCHEMBL6771329 0.81 ALDH1A1 (0.49) HTR1AHTR7DRD2HTR6ALDH1A1
SCHEMBL6766414 0.80 SMN1; SMN2 (0.47) HTR1AHTR7DRD2ALDH1A1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6821967-B2 AMINES SUCH AS 9-(4-(4-(BENZOTHIAZOL-2-YL)-PIPERAZIN-1-YL)-BUTYL)-9H-FLUORENE-9-CARBOXYLIC ACID (2,2,2-TRIFLUOROETHYL) AMIDE, USED AS MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN ANTAGONISTS, TO PREVENT ATHEROSCLEROSIS OR HYPERLIPEMIA BOEHRINGER INGELHEIM PHARMA KG (DE) 2004-11-23 US disclosed
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) 2003-09-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166637-A1 Substituted piperazine derivatives, the preparation thereofand their use as medicaments MTTP, CETP, CPT1A CCR5 2567/4885HTR1A 1523/4885HTR7 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.